Intra- and Interobserver Agreement in the Assessment of Human Embryos

the Focus of This Study is to Measure the Intra- and Interobserver Agreement for the Evaluation of Early Stage Embryos Clinical Trial

Official title:

Intra-and Inter-observer Agreement in the Morphological Assessment of Human Embryos

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01802801
• Other study ID #: GP12122007
• Status: Completed
• Phase: N/A
• First received: March 25, 2010
• Last updated: February 28, 2013
• Start date: December 2007
• Est. completion date: August 2009

Study information

• Verified date: February 2013
• Source: University Hospital, Gasthuisberg
• Contact: n/a
• Is FDA regulated: No
• Health authority: Belgium: Federale Commissie voor medisch en wetenschappelijk onderzoek op embryo's in vitro
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to determine the intra- and interobserver agreement.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: August 2009
• Est. primary completion date: July 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: N/A to 3 Days

Eligibility

Inclusion Criteria:

• fertilized embryos

Exclusion Criteria:

• unfertilized embryos

Study Design

N/A

Related Conditions & MeSH terms

• the Focus of This Study is to Measure the Intra- and Interobserver Agreement for the Evaluation of Early Stage Embryos

Intervention

Other:
• embryo development
intra- and inter-observator analysis

Locations

Country	Name	City	State
Belgium	University Hospital Leuven, Catholic University Leuven	Leuven

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Gasthuisberg

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Evaluation of the intra- and inter-observer variability in the assessement of human embryos	Variation in observer assessment of embryo characteristics on day 1, 2 and 3 of embryo development. Assessment of these characteristics is standard procedure. Safety and tolerability or efficacy issues are not relevant for this outcome.		No